Amgen
AMGN
Market cap $156B

295.22 USD

-2.07

0.70%

At close Jun 13, 4:00 PM EDT

After hours

295.00

-0.22

0.07%

1 day

-0.70%

5 days

1.64%

1 month

9.16%

3 months

-5.57%

6 months

9.09%

Year to date

13.86%

1 year

-1.10%

5 years

34.33%

10 years

89.12%

About: Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Employees: 28,000

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 37 [Q4 2024] → 74 (+37) [Q1 2025]

91% more first-time investments, than exits

New positions opened: 245 | Existing positions closed: 128

17% more capital invested

Capital invested by funds: $112B [Q4 2024] → $131B (+$19.4B) [Q1 2025]

2% more funds holding

Funds holding: 2,810 [Q4 2024] → 2,862 (+52) [Q1 2025]

8% more call options, than puts

Call options by funds: $2.74B | Put options by funds: $2.55B

0.69% more ownership

Funds ownership: 77.62% [Q4 2024] → 78.31% (+0.69%) [Q1 2025]

4% less repeat investments, than reductions

Existing positions increased: 1,113 | Existing positions reduced: 1,160

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$280

5%

downside

Avg. target

$311

5%

upside

High target

$330

12%

upside

7 analyst ratings

2 positive

29%

5 neutral

71%

0 negative

0%

Guggenheim Vamil Divan	2%downside $288	Neutral Assumed	20 May 2025
Piper Sandler David Amsellem	11%upside $328	Overweight Maintained	16 May 2025
Mizuho Salim Syed	5%downside $280	Neutral Maintained	7 May 2025
UBS Trung Huynh	7%upside $315	Neutral Maintained	2 May 2025
RBC Capital Gregory Renza	8%upside $320	Outperform Maintained	2 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 33 articles about AMGN published over the past 30 days

Amgen: Imdelltra Data And Q1 Results Impress

Despite the weak performance of Amgen's rare disease portfolio, it once again beat consensus non-GAAP EPS and revenue estimates. So, the main contributors to strengthening Amgen's balance sheet and improving its margins in the first quarter of 2025 were Blincyto, Tezspire, Prolia, and Imdelltra. In its oncology franchise, I highlight Imdelltra as the 'crown jewel,' with sales of $81 million in the first three months of 2025, up 20.9% quarter-on-quarter.

Amgen: Imdelltra Data And Q1 Results Impress

Zacks Investment Research

Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider

Amgen (AMGN) closed at $297.29 in the latest trading session, marking a +1.88% move from the prior day.

Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider

Zacks Investment Research

Here's Why Amgen (AMGN) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Amgen (AMGN) is a Strong Momentum Stock

Amgen Inc. (AMGN) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Amgen Inc. (NASDAQ:AMGN ) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 9:20 PM ET Company Participants James E. Bradner - Executive Vice President of Research & Development Justin G.

Amgen Inc. (AMGN) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Zacks Investment Research

Why Amgen (AMGN) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Amgen (AMGN) is a Top Growth Stock for the Long-Term

Zacks Investment Research

Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Zacks Investment Research

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Investors Business Daily

The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.

The Motley Fool

2 Dividend Growth Stocks to Buy and Hold Forever

When broader equities are volatile, it's tempting to focus on what's going to happen in the near term. That's why some investors resort to panic selling -- they anticipate that things will get even worse than they already are.

2 Dividend Growth Stocks to Buy and Hold Forever

Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies

Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs like MariTide and olpasiran to offset losses. Recent financials show solid revenue growth and improved margins, though net selling prices and legacy drugs like Enbrel remain under pressure. Valuation analysis reveals AMGN is priced for no growth, offering 27% upside if the company achieves even modest revenue increases.

Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies

See News Rankings

Charts implemented using Lightweight Charts™